⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324369 | 0.79 | — | — | |
| SCHEMBL15553434 | 0.77 | — | — | |
| SCHEMBL4781387 | 0.77 | — | — | |
| SCHEMBL3701608 | 0.77 | — | — | |
| SCHEMBL1238343 | 0.77 | — | — | |
| SCHEMBL17773175 | 0.77 | ALDH1A1 (0.51) | — | |
| SCHEMBL472995 | 0.77 | CSNK2A2 (0.42) | — | |
| SCHEMBL11650054 | 0.77 | USP2 (0.46) | — | |
| SCHEMBL568626 | 0.77 | HCAR2 (0.38) | — | |
| Formaldehyde SCHEMBL27847261 | 0.76 | HCAR2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023211854-A1 | KCNT1 INHIBITORS COMPRISING A THIAZOLE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7652146-B2 | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652146-B2 | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090149650-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-11 | — | — | US | disclosed |
| US-7491725-B2 | purification of crystalline N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (IV) using ethanol/water mixture; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491725-B2 | purification of crystalline N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (IV) using ethanol/water mixture; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |